Interventions of Interest
For questions please contact [email protected].
- tavapadon (AbbVie Inc.)
Parkinson’s Disease
An assessment of tavapadon
Public Meeting
October 2026
Assessment Status
Open
Upcoming Milestone
Draft Evidence ReportView
Main Review
October 1, 2026
CTAF
The CTAF 2026 public meeting on treatment for Parkinson’s Disease
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- AbbVie Inc.
- American Parkinson’s Disease Association
- Amneal Pharmaceuticals
- Davis Phinney Foundation
- Humana
- Michael J Fox Foundation
- Parkinson’s Foundation
- Parkinson’s and Movement Disorders Alliance
- Union Chimique Belge (UCB)
- Veterans Affairs
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Related Assessments & Policy Papers.
Amyotrophic Lateral Sclerosis (ALS)
Aug 2022Alzheimer’s Disease
Jul 2021Alzheimer’s Disease
Mar 2023
04/16/2026
Research Protocol
Please find the research protocol here: https://osf.io/thkp9/files/tc8su
06/03/2026
Model Analysis Plan
Please find the model analysis plan here: https://osf.io/thkp9/files/tx7n5
09/16/2026
Evidence Report
10/01/2026
Evidence Presentation
11/02/2026
Public Comments
Closed